Raymond James initiated coverage of Korro Bio (KRRO) with a Strong Buy rating and $153 price target The firm believes RNA editing will provide better therapeutic modality than DNA editing and/or RNAi for numerous genetic diseases. It notes Korro’s lead asset, KRRO-110, will soon enter clinical development for alpha-1 antitrypsin deficiency. The shares offer an attractive risk/reward profile ahead of Korro’s data in the second half of 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio initiated with a Strong Buy at Raymond James
- Korro Bio price target raised to $115 from $100 at H.C. Wainwright
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302
- Korro Bio Inc trading resumes